Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Serum S-100β Elevated in Septic Shock Patients with Delirium

By LabMedica International staff writers
Posted on 30 Aug 2018
A high prevalence of delirium is observed in sepsis, yet specific markers for this brain dysfunction in sedated patients are still lacking. More...
Cytoplasmic low molecular weight calcium-binding protein, S-100β, is a commonly used nonspecific marker for brain injury.

S-100β is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S-100β. It has been shown that S-100β is only expressed by a subtype of mature astrocytes that ensheath blood vessels and by NG2-expressing cells. Increases in S-100β levels have been evaluated whether there is an association in patients with delirium.

Scientists at the University of Oulu (Oulu, Finland) carried out an observational study included 22 patients with septic shock. Delirium was assessed by the Confusion Assessment Method (CAM) score for use in intensive care unit patients (CAM-ICU). Blood samples were obtained to measure inflammatory biomarkers: C-reactive protein (CRP), Procalcitonin (PCT), interleukin-6 (IL-6), IL-17, Tumor necrosis factor-alpha (TNF-α) and cerebral biomarkers such as S-100β, neuron-specific enolase (NSE), and two others. Patients were categorized according to the presence of delirium.

The scientists found that delirium was present in 10/22 of the patients (45.5%). Serum S-100β levels were above the laboratory cutoff value of 0.15 μg/L in 13/22 (59.1%) of the patients. The odds ratio for risk of developing delirium in cases with an S-100β greater than 0.15 μg/L was 18.0. Patients with delirium had higher plasma levels of IL-6 compared to those without; 138.3 pg/mL (range: 28.0-296.7) versus 53.6 pg/mL (range 109.3-505). There was a positive correlation between S100-β and IL-6 levels. Delirium patients had higher SOFA scores; 10 versus 7.

The authors concluded that delirium in septic shock was associated with an elevated protein S-100β when using a laboratory cutoff value of 0.15 μg/L and with more severe organ dysfunction during the ICU stay. The study was published on August 5, 2018, in the journal Acta Anaesthesiologica Scandinavica.

Related Links:
University of Oulu


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.